Roche Diagnostics Launches Two Cancer Drug Testing Agents In Japan
This article was originally published in PharmAsia News
Executive Summary
Roche Diagnostics plans to launch the biomarker KRASfor Merck Serono's colon cancer drug Erbitux (cetuximab) in March. KRAS will be used to test genotypes when administering colon cancer drugs to decide the relationship between genotypes and drug efficacy. The company also plans to launches EGFRtesting for lung cancer drugs this summer, which will be used to assess efficacy of AstraZeneca's Iressa (gefitinib) and Chugai's Tarceva (erlotinib). (Click here for more - Japanese language